What the EU is trying to do with this trade agreement is effectively slowly poison the production of affordable generic medicines in India, which has helped keep so many people alive. This trade agreement could target us as treatment providers, simply for buying generic medicines from India to treat patients in our programs.
Head of Mission for MSF in India
India has been called the “pharmacy of the developing world” because it produces a large number of high-quality, affordable generic medicines. MSF and other treatment providers also rely on Indian generic medicines to treat other diseases and conditions.
However, a free trade agreement (FTA) currently under negotiation between the European Union (EU) and India could greatly restrict the ability of Indian generic manufacturers to continue producing high-quality, affordable medicines that millions of people with HIV/AIDS and other diseases and conditions rely on to stay alive.